千亿创新药巨头 又出手并购

Core Viewpoint - China Biopharmaceutical has acquired 100% equity of Hejia Bio for 1.2 billion RMB, enhancing its position in the small RNA (siRNA) sector, following its previous acquisition of Lixin Pharmaceutical for approximately 3.5 billion RMB in July 2025 [2]. Group 1: Acquisition Details - The acquisition of Hejia Bio is a strategic move to strengthen China Biopharmaceutical's capabilities in the siRNA field, marking another significant investment after the acquisition of Shengyin Bio [2]. - Hejia Bio, established in 2018, focuses on innovative siRNA products with advantages in long-lasting effects and low dosage, boasting six delivery platforms and four innovative drugs in clinical stages [2][3]. Group 2: Product Pipeline and Innovation - Hejia Bio's Kylo-11, targeting LPA, is the world's first siRNA product to achieve "one injection per year" in clinical trials, with the first patient treated in a multi-center Phase II trial in October 2025 [3]. - In addition to Kylo-11, Hejia has three other clinical projects and over 20 preclinical pipelines covering high-value areas such as cardiovascular, metabolic, and neurological diseases [3]. Group 3: Market Expansion and Strategic Goals - The acquisition allows China Biopharmaceutical to complete its innovative drug layout in the cardiovascular field and significantly expand into major chronic disease areas such as weight management and neuropsychiatric disorders [4]. - The chairman of China Biopharmaceutical emphasized that Hejia Bio's differentiated delivery technology platform will enhance the group's core competitiveness in the siRNA sector and open up new opportunities in the global trillion-dollar chronic disease treatment market [4]. Group 4: Industry Insights - Industry experts view the acquisition as a strategic complement to China Biopharmaceutical's technical and commercialization capabilities, potentially accelerating the market introduction of Hejia's siRNA drug pipeline [5]. - The global average transaction amount for small RNA business development (BD) deals is projected to exceed 800 million USD in 2024, indicating that the acquisition aligns with the industry's growth trajectory and valuation opportunities [5].